Tumor News and Research

RSS

Celebrex may one day be used to prevent and even treat breast tumors

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

5 Nov 2004

Cellular vehicle delivers drugs directly into cancer cells

Researchers at The University of Texas M. D. Anderson Cancer Center have perfected a delivery system for anticancer treatment that zeroes in on a tumor and becomes part of its supporting tissue.

4 Nov 2004

Sensor protein that identifies DNA breaks and activates the p53 cell-death program has been identified

DNA breaks from radiation, toxic chemicals, or other environmental causes occur routinely in cells and, unless promptly and properly repaired, can lead to cancer-causing mutations.

4 Nov 2004

STAT3 protein could lead to new ways to prevent skin cancer

Scientists at The University of Texas M. D. Anderson Cancer Center have identified a protein that serves as a master regulator of skin cancer - a finding that could lead to new ways to prevent skin cancer before it starts.

4 Nov 2004

FDA fast tracks investigational anti-cancer drug, phenoxodiol

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, Fast Track status for its intended use in patients with recurrent ovarian cancer.

4 Nov 2004

The Bush Medicare Prescription has changed the identity of medical oncology

Under previous law, Medicare covered chemotherapy as well as radiation treatment for cancer patients, but did not pay for oral-dose anti-cancer drugs, unless they were available in both oral and injectable form.

4 Nov 2004

Less risks for patients participating in early phase cancer drug trials

The risk of treatment-related (toxic) death for cancer patients enrolled in phase 1 clinical trials had decreased significantly over the past 12 years (from 1991 to 2002), according to an article in the November 3 issue of JAMA.

3 Nov 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004

Scientists have uncovered a significant new link in the chain of immune system events through which estrogen prevents bone loss

Through research in mice, the scientists discovered that an immune signaling molecule called type b transforming growth factor (TGFb) is responsible for a cascade of events that leads estrogen to prevent bone loss.

29 Oct 2004

New direction for spinal cord research

A piece of the puzzle of how nerves find their way across the midline of the brain and spinal cord in a developing embryo has been found by Medical College of Georgia researchers.

28 Oct 2004

Potential new treatment strategy against metastatic cancer cells

A team of scientists at The Scripps Research Institute has identified a potential treatment strategy against metastatic cancer cells that has never been tried before.

25 Oct 2004

High levels of a protein called LRP6 can make cancer cells more aggressive

The protein's ability to enhance tumor development suggests that the gene that codes for LRP6 is an oncogene--a gene that contributes to tumor development when overactivated.

25 Oct 2004

Potential new protein marker for prognosis of breast and ovarian cancer

The researchers matched tumor samples to outcomes in about 100 patients diagnosed with either breast or ovarian cancer and found that a low level of Rab25 protein on a patient's cancer sample was associated with a better clinical outcome in both cancer types.

24 Oct 2004

Discovery of new protein involved in regulating the second most commonly mutated tumor suppressor in human tumors

Scientists in Tokyo have discovered a new protein, named PICT-1, that is involved in regulating PTEN, the second most commonly mutated tumor suppressor in human tumors.

22 Oct 2004

Lag-3 gene dampens immune responses by controlling regulatory T-cell function

The discovery that the Lag-3 gene acts as a brake to prevent immune system responses from running out of control solves a mystery that has puzzled researchers since the gene was discovered 14 years ago.

22 Oct 2004

Stem cells grown from skin samples of adult patients with brain tumors could be used as a new brain tumor therapy

A team of neurosurgeons and scientists from Italy is looking into whether stem cells derived from a brain tumor patient's own skin can be used to fight the tumors.

21 Oct 2004

Researchers have uncovered a specific signaling mechanism that contributes to the development of colorectal cancer

The discovery furthers the understanding of mechanisms that contribute to disease progression and provides new avenues for development of therapies for colorectal cancer.

21 Oct 2004

Genetic predictions may bring “quantum leap” in breast cancer treatment success

Researchers at Virginia Commonwealth University’s Massey Cancer Center received a prestigious award and a $600,000 grant from the V Foundation for Cancer Research, one of the nation’s leading organizations devoted exclusively to funding cancer research.

20 Oct 2004

Nano-bullet for non-invasive treatment of cancers

Virginia Commonwealth University physicists, working with one of the most precious materials on Earth – gold -- and with one of the most common – sand -- have created a so-called “nano-bullet” that targets tumors and may help scientists develop non-invasive cancer treatments.

20 Oct 2004

Scientists have devised a novel way to repair one of the genetic mutations that causes ataxia-telangiectasia

UCLA scientists have devised a novel way to repair one of the genetic mutations that causes ataxia-telangiectasia, (A-T), a life-shortening disorder that devastates the neurological and immune systems of one in 40,000 young children.

19 Oct 2004